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Abstract: Flavonoids are abundant polyphenols in nature. They are extensively biotransformed
in enterocytes and hepatocytes, where conjugated (methyl, sulfate, and glucuronide) metabolites
are formed. However, bacterial microflora in the human intestines also metabolize flavonoids,
resulting in the production of smaller phenolic fragments (e.g., hydroxybenzoic, hydroxyacetic and
hydroxycinnamic acids, and hydroxybenzenes). Despite the fact that several colonic metabolites
appear in the circulation at high concentrations, we have only limited information regarding
their pharmacodynamic effects and pharmacokinetic interactions. Therefore, in this in vitro
study, we investigated the interactions of 24 microbial flavonoid metabolites with human serum
albumin and cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes. Our results demonstrated
that some metabolites (e.g., 2,4-dihydroxyacetophenone, pyrogallol, O-desmethylangolensin, and
2-hydroxy-4-methoxybenzoic acid) form stable complexes with albumin. However, the compounds
tested did not considerably displace Site I and II marker drugs from albumin. All CYP isoforms
examined were significantly inhibited by O-desmethylangolensin; nevertheless, only its effect
on CYP2C9 seems to be relevant. Furthermore, resorcinol and phloroglucinol showed strong
inhibitory effects on CYP3A4. Our results demonstrate that, besides flavonoid aglycones and their
conjugated derivatives, some colonic metabolites are also able to interact with proteins involved in
the pharmacokinetics of drugs.
Keywords: polyphenols; colonic flavonoid metabolites; pharmacokinetic interaction; serum albumin;
CYP450 enzymes; resorcinol; phloroglucinol; O-desmethylangolensin
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1. Introduction
Flavonoids, phenolic compounds found in numerous plants (including fruits and vegetables) [1],
have been demonstrated to have beneficial health effects in several in vitro and in vivo studies [2,3].
Therefore, flavonoid-containing dietary supplements are widely marketed through the Internet.
Some of these dietary supplements contain extremely high doses of flavonoids (ranging from
several hundreds to thousands of milligrams) [4,5]. Furthermore, flavonoids can interact with
proteins involved in drug pharmacokinetics, such as serum albumin, biotransformation enzymes,
and drug transporters [6–8]. Therefore, the high intake of flavonoids may cause pharmacokinetic
interactions with clinically used drugs, as has been reviewed in several papers [9–11]. The oral
bioavailability of parent flavonoids is low due to their physicochemical properties and high presystemic
elimination [12]. In general, flavonoid aglycones are extensively conjugated even in enterocytes and
later in hepatocytes, resulting in the production of methyl, sulfate, and glucuronide metabolites [12,13].
A large fraction of flavonoids, not absorbed from the small intestines, can be biotransformed by the
colon microbiota, leading to the degradation of flavonoid ring(s) to smaller phenolic compounds.
The colonic metabolites can be classified as hydroxybenzoic, hydroxyacetic and hydroxycinnamic
acids, and hydroxybenzenes (Figure 1) [14–17]. Typically, the microbial metabolites of flavonols
are phenylacetic and phenylpropionic acids, while flavones and flavanones are biotransformed
into phenylpropionic acids (then to benzoic acid) [13]. For example, 3-hydroxyphenylacetic,
3-methoxy-4-hydroxyphenylacetic and 3,4-dihydroxyphenylacetic acids were identified as the major
colonic metabolites of quercetin, after the oral administration of quercetin-3-rutinoside to healthy
human subjects [13]. As to pharmacokinetic issues, some colonic metabolites were previously shown
to interact with serum albumin or biotransformation enzymes, such as pyrogallol (PYR) which form a
stable complex with albumin [18], and it is a potent inhibitor of xanthine oxidase enzyme [19,20].
Human serum albumin (HSA) has a major role in the transport of several drugs and xenobiotics
in the human circulation [21,22]. There are two major drug binding sites of HSA: the Sudlow’s Site I
(subdomain IIA) and Site II (subdomain IIIA) [21]. Displacement of drugs from HSA leads to their
elevated free plasma concentrations, which can affect the tissue uptake and/or the speed of elimination
of the displaced compound [22]. Cytochrome P450 (CYP) is a superfamily of heme-containing
microsomal enzymes [23]. CYP enzymes are crucial in the biotransformation of a wide range of
xenobiotics, including drugs and environmental toxins [23,24]. CYP3A4 is the main isoenzyme
expressed in the liver and intestines. More than 50% of the orally administered drugs are metabolized
by CYP3A4; however, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 are also commonly involved in drug
metabolism [25].
Only limited information is available regarding the plasma concentrations of colonic metabolites;
however, most of them can be absorbed from the colon. After the high consumption of some fruits (e.g.,
cranberry), tea, and/or products produced from them, the plasma concentrations of certain microbial
flavonoid metabolites can exceed 10 µM [26,27]. These observations suggest that some metabolites
may also achieve relevant concentrations in tissues, which is likely enhanced by the extremely high
intake of flavonoids through dietary supplements [4].
In this study, we aimed to investigate the interaction of 24 colonic flavonoid metabolites with
HSA and CYP (2C9, 2C19, and 3A4) enzymes. HSA-ligand interactions were examined employing
fluorescence spectroscopy. Displacement of Site I (warfarin) and Site II (naproxen) markers from HSA
by test compounds was evaluated based on ultrafiltration. The inhibitory effects of the metabolites
on CYP enzymes were tested in vitro, the substrates and the formed metabolites were quantified by
high-performance liquid chromatography (HPLC).
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Figure 1. Chemical structures of resorcinol (RES), 4-methylcatechol (4MC), pyrogallol (PYR),
phloroglucinol (PHLO), benzoic acid (BA), 4-hydroxybenzoic acid (4HBA), 2,4-dihydroxybenzoic
acid (24DHBA), 2-hydroxy-4-methoxybenzoic acid (2H4MBA), 3,4-dihydroxybenzoic acid (34DHBA),
2,4-dihydroxyacetophenone (24DHAP), 2-hydroxyphenylacetic acid (2HPAA), 4-hydroxyphenylacetic
acid (4HPAA), 3,4-dihydroxyphenylacetic acid (34DHPAA), 3-hydroxy-4-methoxyphenylacetic acid
(3H4MPAA), 3-methoxy-4-hydroxyphenylacetic acid (3M4HPAA), 4-(hydroxymethyl)phenylacetic acid
(4HMPAA), 3-phenylpropionic acid (3PPA), 3-(3-hydroxyphenyl)propionic acid (33HPPA), 3-coumaric
acid (3CA), 3-(4-hydroxyphenyl)propionic acid (34HPPA), 3-(2,4-dihydroxyphenyl)propionic acid
(324DHPAA), 3-(3,4-dihydroxyphenyl)propionic acid (334DHPPA), O-desmethylangolensin (DESMA),
and hippuric acid (HIPA).
2. Materials and Methods
2.1. Reagents
Human serum albumin (HSA), warfarin, naproxen, testosterone, 6β-hydroxytestosterone,
ketoconazole, ticlopidine hydrochloride, CypExpressTM 2C9 kit, CypExpressTM 2C19 kit, CypExpressTM
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3A4 kit, resorcinol (RES; benzene-1,3-diol), 4-methylcatechol (4MC; 4-methylbenzene-1,2-diol),
pyrogallol (PYR; benzene-1,2,3-triol), phloroglucinol (PHLO; 1,3,5-trihydroxybenzene), benzoic acid
(BA), 4-hydroxybenzoic acid (4HBA), 2,4-dihydroxybenzoic acid (24DHBA; 4-hydroxysalicylic acid),
2-hydroxy-4-methoxybenzoic acid (2H4MBA; 4-methoxysalicylic acid), 3,4-dihydroxybenzoic acid
(34DHBA; protocatechuic acid), 2,4-dihydroxyacetophenone (24DHAP), 2-hydroxyphenylacetic acid
(2HPAA), 4-hydroxyphenylacetic acid (4HPAA), 3,4-dihydroxyphenylacetic acid (34DHPAA),
3-hydroxy-4-methoxyphenylacetic acid (3H4MPAA), 3-methoxy-4-hydroxyphenylacetic
acid (3M4HPAA; homovanillic acid), 4-(hydroxymethyl)phenylacetic acid (4HMPAA),
3-phenylpropionic acid (3PPA; hydrocinnamic acid), 3-coumaric acid (3CA; 3-hydroxycinnamic acid),
3-(4-hydroxyphenyl)propionic acid (34HPPA; phloretic acid), 3-(2,4-dihydroxyphenyl)propionic
acid (324DHPAA; 3,4-dihydroxy-hydrocinnamic acid), hippuric acid (HIPA; benzoylaminoacetic
acid) were obtained from Sigma-Aldrich (St. Louis, MO, US). 3-(3-hydroxyphenyl)propionic acid
(33HPPA) and 3-(3,4-dihydroxyphenyl)propionic acid (334DHPPA; 3,4-dihydroxyphenylcinnamic
acid) were purchased from Toronto Research Chemicals (North York, Ontario, Canada). Racemic
O-desmethylangolensin (DESMA; 1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)-1-propanone) was
synthetized as described previously [28]. S-mephenytoin, 4-hydroxymephenytoin, diclofenac,
4′-hydroxydiclofenac, and sulfaphenazole were obtained from Carbosynth (Berkshire, UK). Flavonoid
metabolites were dissolved in dimethyl sulfoxide (DMSO; Fluka, Bucharest, Romania), and stock
solutions (10 mM) were stored at −20 ◦C.
2.2. Spectroscopic Measurements
Albumin-ligand interactions were investigated employing a Hitachi F-4500 fluorimeter (Tokyo,
Japan), measurements were performed in phosphate-buffered saline (PBS, pH 7.4), in the presence of
air at room temperature. Absorption spectra of the flavonoid metabolites were also recorded in PBS,
applying a HALO DB-20 UV-Vis spectrophotometer (Dynamica, London, UK). Because the inner filter
effect can decrease the fluorescence emission signal of albumin, fluorescence spectra were corrected
using the following equation [29,30]:
Icor = Iobs × e(Aex + Aem)/2 (1)
where Icor means the corrected and Iobs denotes the observed emission intensities at the wavelengths
used, while Aex and Aem are the absorbance values of flavonoid metabolites at the excitation and
emission wavelengths applied, respectively.
HSA-ligand interactions were evaluated using fluorescence quenching studies or the intrinsic
fluoresce of the metabolite (if it strongly interfered with the emission signal of albumin). In quenching
studies, the emission spectrum of HSA (2 µM) was recorded in the presence of increasing concentrations
of microbial metabolites (0, 2, 3, 4, 5, 6, and 8 µM), using a 295 nm excitation wavelength. Data were
evaluated based on linear and non-linear fitting, employing the Stern-Volmer equation (Equation (2))
and the Hyperquad2006 program package (Protonic Software; Leeds, UK) [30,31], respectively. The
Stern-Volmer equation was described as
I0/I = 1 + KSV × [Q] (2)
where I0 and I denote the fluorescence emission intensities (λex = 295 nm, λem = 340 nm) of HSA in the
absence and presence of colonic metabolites, respectively. Furthermore, KSV (unit: L/mol) and [Q] (unit:
mol/L) are the Stern-Volmer quenching constant and the concentration of the quencher, respectively.
Since 2H4MBA showed strong fluorescence at the emission maximum of HSA (340 nm), the
interaction of 2H4MBA with albumin was investigated based on the increase in its emission signal
in the presence of HSA at 395 nm. The fluorescence emission spectrum of 2H4MBA (2 µM) was
recorded with HSA (0, 0.5, 1, 2, 3, 4 and 5 µM), using 295 nm excitation wavelength (the excitation
maximum of 2H4MBA). The binding constants (K; unit: L/mol) of albumin-ligand complexes were
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determined by non-linear fitting using the Hyperquad2006 program, as has been reported [30,31].
During this evaluation, absorbance values and fluorescence signals of both HSA and 2H4MBA were
taken into account.
2.3. Ultrafiltration Experiments
The displacing effects of colonic flavonoid metabolites vs. Site I marker warfarin and Site II marker
naproxen were examined based on ultrafiltration, employing the previously described methods [32,33].
Briefly, samples containing warfarin with HSA (1 and 5 µM, respectively) or naproxen with HSA (1 and
1.5 µM, respectively) both without and with flavonoid metabolites (20 µM) were filtered, employing
Pall Microsep Advance centrifugal devices (30 kDa molecular weight cut-off value; VWR, Budapest,
Hungary). Then the concentrations of site markers in the filtrates were quantified by HPLC (see in 2.5).
2.4. CYP Assays
The inhibitory effects of colonic flavonoid metabolites were examined in vitro, applying
CypExpressTM Cytochrome P450 human kits. In each assay, FDA-recommended substrates (CYP2C9:
diclofenac; CYP2C19: S-mephenytoin; CYP3A4: testosterone) and positive controls (CYP2C9:
sulfaphenazole; CYP2C19: ticlopidine; CYP3A4: ketoconazole) were used as well as solvent controls.
Inhibition of CYP2C9 enzyme was examined based on CYP2C9-catalyzed 4′-hydroxydiclofenac
formation in the presence of microbial metabolites, using the previously reported method with some
modifications [32,33]. Briefly, each incubate (with a 200-µL final volume) contained diclofenac (5 µM;
substrate) and CypExpressTM 2C9 kit (6 mg/mL; including the NADPH generating system), in the
presence of test compounds (0–30 µM) or the positive control (sulfaphenazole), in 0.05 M potassium
phosphate buffer (pH 7.5). The incubations were started with the addition of the enzyme. After 120
min incubation at 700 rpm and 30 ◦C in a thermomixer (Eppendorf, Hamburg, Germany), the reaction
was stopped with the addition of 100 µL of ice-cold methanol. After centrifugation (10 min, 14,000 g,
room temperature), the concentrations of diclofenac and 4′-hydroxydiclofenac were quantified with
HPLC (see in 2.5).
Effects of microbial metabolites on CYP2C19 enzyme were examined based on their impact on
CYP2C19-catalyzed 4-hydroxymephenytoin formation, employing the previously reported method
without modifications [33].
Inhibitory action of flavonoid metabolites on CYP3A4 enzyme was tested based on their effects
on CYP3A4-catalyzed testosterone hydroxylation, using the previously described method without
modifications [32,33].
The metabolite formation (% of control) was depicted vs. the concentrations of inhibitors in
a decimal logarithmic scale, then IC50 values were determined employing the GraphPad Prism 8
software (San Diego, CA, USA).
2.5. HPLC Analyses
The following HPLC system was used to quantify site markers as well as substrates and products
of CYP enzymes: Waters 510 pump (Milford, MA, USA), Rheodyne 7125 injector (Berkeley, CA, USA)
with a 20-µL sample loop, Waters 486 UV detector (Milford, MA, USA), and Jasco FP-920 fluorescence
detector (Tokyo, Japan). The data were evaluated using Waters Millennium Chromatography Manager
(Milford, MA, USA).
After ultrafiltration, warfarin and naproxen (Site I and II markers of HSA, respectively)
concentrations in the filtrates were quantified directly, using the previously described methods
without modifications [32,33], by fluorescence and UV detectors, respectively.
Diclofenac and 4′-hydroxydiclofenac (CYP2C9 assay) were quantified by HPLC-UV as it was
reported previously [32,33]. However, DESMA was co-eluted with the substrate; therefore, the
following HPLC method was used to determine its inhibitory effect on CYP2C9 enzyme. The
separation was carried out using a guard column (Phenomenex Security Guard C8, 4.0 × 3.0 mm)
Biomolecules 2020, 10, 409 6 of 19
linked to an analytical column (Agilent Eclipse C8, 150 × 4.6 mm, 5 µm) at room temperature. The
mobile phase contained sodium phosphate buffer (10 mM, pH 4.55) and acetonitrile (60:40 v/v%), and
was driven through the column with 1.0 mL/min (0–7.5 min) then with 1.2 mL/min (7.5–13 min) flow
rate. Diclofenac and 4′-hydroxydiclofenac were detected at 275 nm.
S-mephenytoin and 4-hydroxymephenytoin (CYP2C19 assay) as well as testosterone and
6β-hydroxytestosterone (CYP3A4 assay) were quantified by HPLC-UV employing the previously
described methods without modifications [32,33].
2.6. Modeling Studies
Ligand structures of DESMA, RES, and PHLO were built in Maestro [34] and energy-minimized
using quantum chemistry program package, MOPAC [35] with a PM7 parametrization [36]
and a gradient norm set to 0.001. Force calculations were also performed using MOPAC, the
force constant matrices were positive definite. Gasteiger-Marsilli partial charges were assigned
in AutoDock Tools [37]. Flexibility was allowed on the ligand at all active torsions. These
prepared structures were used for docking. In the IUPAC name of O-desmethylangolensin
(1-(2,4-dihydroxyphenyl)-2-4-hydroxyphenyl)propan-1-one), there is no information about chirality.
Based on previous studies, dominantly R(-)-DESMA is produced (approximately 90%) in the human
body [38–40]. In the present study, we docked both the R- and S- configurations of this ligand.
The apo structures of CYP3A4 were thoroughly investigated to select the target. For CYP2C9 only
one apo structure was available. Atomic coordinates of the targets were obtained from the Protein
Data Bank (PDB). Apo structures of CYP3A4 (PDB code 5vcc) and CYP2C9 (PDB code 1og2) were used
for docking of ligands DESMA, RES, and PHLO. The holo structure of CYP2C9 (PDB code 1og5) used
to test the applicability of the method, the original crystallographic ligand S-warfarin was redocked
onto the target.
Atomic partial charges of heme were adopted as the ferric penta coordinate high spin charge
model from reference [41]. The rest of the target molecule was equipped with polar hydrogen atoms
and Gasteiger-Marsilli partial charges in AutoDock Tools as in our previous study [42].
All ligand structures were docked to the active site of the enzymes located above the heme ring
using AutoDock 4.2.6 [37]. The number of grid points was set to 90×90×90 at a 0.375 Å grid spacing.
Lamarckian genetic algorithm was used for global search, with the flexibility of all active torsions
allowed on the ligand. Ten docking runs were performed, and the resultant ligand conformations
were ranked by their free binding energy values. Representative docked ligand conformations were
used to collect interacting target amino acid residues with a 3.5 Å cut-off distance calculated for heavy
atoms. Root mean squared deviation (RMSD) values were calculated between the heavy atoms of the
crystallographic and representative ligand conformations.
2.7. Statistics
Data demonstrate mean and standard error of the mean (±SEM) values, derived at least from
three independent experiments. Statistical significance (p < 0.05 and p < 0.01) was evaluated
based on one-way ANOVA test followed by Tukey’s post-hoc test (IBM SPSS Statistics, Version 21;
Armonk, NY, USA).
3. Results
3.1. Interaction of Colonic Flavonoid Metabolites with Human Serum Albumin Determined by Fluorescence
Spectroscopy
To investigate the potential interactions of colonic metabolites with HSA, fluorescence quenching
experiments were performed. Among the 24 metabolites tested, 3CA, 24DHAP, PYR, and DESMA
caused significant decrease in HSA fluorescence signal at 340 nm (λex = 295 nm; Figure 2). DESMA
induced the strongest decrease in the emission of HSA, followed by PYR, 24DHAP, and 3CA. The
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quenching effects of colonic metabolites on HSA was evaluated employing the Stern-Volmer equation
(Equation (2)). Stern-Volmer plots and decimal logarithmic KSV values are demonstrated in Figure 3
and Table 1, respectively. After the elimination of inner-filter effects of compounds tested, Stern-Volmer
plots showed excellent linearity (R2 = 0.990–0.998), suggesting the static quenching effects of 3CA,
24DHAP, PYR, and DESMA on the fluorescence signal of HSA.
Figure 2. Fluorescence quenching effects of colonic flavonoid metabolites. Representative emission
spectra of HSA (2µM) in the presence of increasing concentrations (0, 2, 3, 4, 5, 6, and 8µM) of 3-coumaric
acid (3CA), 2,4-dihydroxyacetophenon (24DHAP), pyrogallol (PYR), and O-desmethylangolensin
(DESMA) in PBS (pH 7.4; λex = 295 nm).
Figure 3. Stern-Volmer plots of metabolite-HSA complexes (λex = 295 nm, λem = 340 nm). Means and
SEM values are derived from three independent experiments (DESMA, O-desmethylangolensin; PYR,
pyrogallol; 24DHAP, 2,4-dihydroxyacetophenon; 3CA, 3-coumaric acid).
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Table 1. Decimal logarithmic values (±SEM) of Stern-Volmer quenching constants (KSV; unit: L/mol)
and binding constants (K; unit: L/mol) of albumin-ligand complexes. Means and SEM are derived
from three independent experiments. SEM values regarding the fitting to individual data series with
Hyperquad software did not exceed 0.02.
Complex LogKSV LogK
3CA-HSA 4.13 ± 0.02 4.14 ± 0.03
24DHAP-HSA 4.39 ± 0.06 4.56 ± 0.06
PYR-HSA 4.64 ± 0.03 4.68 ± 0.03
DESMA-HSA 4.99 ± 0.01 5.08 ± 0.06
2H4MBA-HSA - 5.14 ± 0.06
2H4MBA exerted significant fluorescence at 340 nm which interfered with the emission signal of
HSA (Figure 4). Therefore, emission spectra of 2H4MBA (2 µM) in the presence of increasing HSA
concentrations (0-5 µM; Figure 4, left) and the same concentrations of HSA alone (without 2H4MBA)
were also recorded (λex = 295 nm). Data were evaluated at the emission wavelength maximum of
2H4MBA (395 nm), where the observed fluorescence signal highly exceeded the sum of the emission
signals of 2H4MBA and HSA (Figure 4, right). This suggests the formation of 2H4MBA-HSA complexes.
Figure 4. Effect of human serum albumin (HSA) on the fluorescence emission signal of
2-hydroxy-4-methoxybenzoic acid (2H4MBA). Left: Representative emission spectra of 2H4MBA
(2 µM) in the presence of increasing concentrations of HSA (0, 0.5, 1, 2, 3, 4 and 5 µM) in PBS (pH 7.4).
Right: Fluorescence emission intensity of 2H4MBA in the presence of increasing concentrations of
HSA (I2H4MBA+HSA), HSA alone (IHSA), and I2H4MBA+HSA – IHSA in PBS (pH 7.4; λex = 295 nm, λem =
395 nm).
Based on quenching studies (Figure 2) and the HSA-induced increase in the fluorescence of
2H4MBA (Figure 4), the binding constants (K) of albumin-ligand complexes were determined by
non-linear fitting, employing the Hyperquad2006 software [30,31]. Table 1 demonstrates the decimal
logarithmic K values, suggesting that 2H4MBA and DESMA binds to albumin with the highest affinity
among the compounds tested. LogK and logKSV values showed excellent correlation.
3.2. Displacement of Site I and II Markers from Human Serum Albumin Determined by Ultrafiltration
To test the displacing ability of 3CA, 24DHAP, PYR, DESMA, and 2H4MBA vs. the Site I marker
warfarin and the Site II marker naproxen, ultrafiltration experiments were performed. PYR (p < 0.01)
and DESMA (p < 0.05) significantly increased the concentration of warfarin in the filtrate (Figure 5,
left). Furthermore, 2H4MBA was the sole compound which induced statistically significant (p < 0.05)
but weak elevation of filtered naproxen concentration (Figure 5, right).
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Figure 5. Displacement of warfarin (WAR; left) and naproxen (NAP; right) from HSA based on
ultrafiltration (*p < 0.05, **p < 0.01). Left: Concentration of WAR in the filtrate after ultrafiltration in
the absence and presence of 3-coumaric acid (3CA), 2,4-dihydroxyacetophenon (24DHAP), pyrogallol
(PYR), O-desmethylangolensin (DESMA), and 2-hydroxy-4-methoxybenzoic acid (2H4MBA) (WAR: 1
µM; HSA: 5 µM). Right: Concentration of NAP in the filtrate after ultrafiltration in the absence and
presence of 3CA, 24DHAP, PYR, DESMA, and 2H4MBA (NAP: 1 µM; HSA: 1.5 µM). Means and SEM
values presented are derived from three independent experiments.
3.3. Inhibition of CYP2C9 Enzyme by Colonic Flavonoid Metabolites
In the following experiments, the inhibitory effects of the microbial flavonoid metabolites on
the CYP2C9-catalyzed diclofenac hydroxylation were examined. Because of the high number of test
compounds, in the first experiments, their four-fold concentration (20 µM) vs. the substrate was
investigated. Among the 24 substances tested, only 24DHAP and DESMA significantly inhibited the
enzyme. 24DHAP caused only a slight inhibition, while DESMA decreased the metabolite formation
even at low micromolar concentrations (Figure 6). Despite the strong inhibitory effect of DESMA, it
showed considerably (five-fold) weaker effect than the positive control sulfaphenazole (Figure 6, right;
Table 2).
Figure 6. Left: Inhibitory effects of colonic flavonoid metabolites and sulfaphenazole (SULF,
positive control; 20 µM each) on the CYP2C9-catalyzed diclofenac (5 µM) hydroxylation.
O-desmethylangolensin (DESMA) was the sole compound which considerably inhibited the enzyme.
Right: Concentration-dependent inhibition of CYP2C9 by DESMA and SULF (* p < 0.05; ** p < 0.01).
Means and SEM values demonstrated are derived from three independent experiments.
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Table 2. Inhibitory effects of DESMA, RES, PHLO, and the positive controls (sulfaphenazole and
ketoconazole) on CYP2C9 or CYP3A4 enzymes. Data are derived from three independent experiments.
CYP2C9 assay Substrate concentration (µM) IC50 (µM) α 1
Sulfaphenazole 5.0 1.32 1.00
DESMA 5.0 6.60 5.00
CYP3A4 assay Substrate concentration (µM) IC50 (µM) α 1
Ketoconazole 5.0 0.24 1.00
RES 5.0 4.86 20.3
PHLO 5.0 7.92 33.0
1α: IC50 of the inhibitor divided by the IC50 value of the positive control.
3.4. Inhibition of CYP2C19 Enzyme by Colonic Flavonoid Metabolites
We also tested the effects of microbial metabolites on CYP2C19-catalyzed S-mephenytoin
hydroxylation. Our results demonstrated that 2H4MBA, 34DHBA, HIPA, and DESMA induced
statistically significant decrease in the metabolite formation at four-fold concentrations (20 µM) vs. the
substrate (Figure 7). However, even these compounds induced less than 30% inhibition, and proved to
be considerably weaker inhibitors than the positive control ticlopidine.
Figure 7. Inhibitory effects of colonic flavonoid metabolites and ticlopidine (TIC, positive
control; 20 µM each) on the CYP2C19-catalyzed S-mephenytoin (5 µM) hydroxylation.
2-hydroxy-4-methoxybenzoic acid (2H4MBA), 3,4-dihydroxybenzoic acid (34DHBA), hippuric acid
(HIPA), and O-desmethylangolensin (DESMA) caused statistically significant (** p < 0.01) but
only weak inhibition of the enzyme. Means and SEM values presented are derived from three
independent experiments.
3.5. Inhibition of CYP3A4 Enzyme by Colonic Flavonoid Metabolites
The inhibitory effects of microbial metabolites on CYP3A4-catalyzed testosterone hydroxylation
were also examined. At four-fold concentrations (20 µM) vs. the substrate, 24DHAP and DESMA
showed less than 30% inhibition of CYP3A4 (Figure 8, left). However, PHLO and RES exerted stronger
inhibitory effect on the enzyme, causing approximately 40% and 65% decrease in metabolite formation
under the same circumstances. The concentration-dependent inhibitory actions of PHLO, RES, and the
positive control ketoconazole are demonstrated in Figure 8 (right), showing that PHLO and RES are
approximately 20- and 30-fold weaker inhibitors of CYP3A4 than ketoconazole, respectively (Table 2).
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Figure 8. Left: Inhibitory effects of colonic flavonoid metabolites and ketoconazole (KET, positive control;
each 20 µM) on the CYP3A4-catalyzed testosterone (5 µM) hydroxylation. 2,4-dihydroxyacetophenone
(24DHAP), O-desmethylangolensin (DESMA), phloroglucinol (PHLO), and resorcinol (RES) caused
statistically significant decrease in metabolite formation. Right: Concentration-dependent inhibition of
CYP3A4 by PHLO, RES, and KET (* p < 0.05; ** p < 0.01). Means and SEM values demonstrated are
derived from three independent experiments.
3.6. Modeling Studies
Docking of S-warfarin served as a test of applicability of the methodology for producing
close-to crystallographic bound ligand conformation. The known heme-bound crystallographic ligand
conformation of S-warfarin was used as a reference for checking the applicability of our computational
docking protocol for atomic resolution calculation of the ligand binding mode. Re-docking of S-warfarin
into the holo CYP2C9 structure (PDB code 1og5) was successful, and the crystallographic ligand
binding mode was reproduced at an RMSD value of 1.24 Å in the top 1st rank. Docking of S-warfarin
was also performed for the apo CYP2C9 (PDB code 1og2) structure at an RMSD value of 4.08 Å (top
3rd rank).
Ligands DESMA, PHLO, and RES were docked to the active sites of both apo enzyme structures
(PDB codes 5vcc and 1og2 for CYP3A4 and CYP2C9, respectively). In the cases of the query ligands,
the binding modes are de novo described in the present study.
Both R- and S-enantiomers of DESMA were docked. Notably, the R-enantiomer is the dominant
metabolite of daidzein (approximately 90% R- vs. 10% S-enantiomer is formed) [38–40]. Interestingly,
the S-enantiomer only found binding positions that appeared to be prerequisite modes if compared
to the R-enantiomer. The latter found a position appearing to be a final binding mode, due to its
unambiguous coordination to the heme iron (Figure 9). Likewise ketoconazole (a well-known inhibitor
of CYP3A4), where the imidazole N atom of ketoconazole coordinates to the heme iron with a distance
of 2.70 Å [42], this binding mode of the R-DESMA was reached in the top 3rd rank with the O atom of
its hydroxyl group being of 3.60 Å distance from the heme iron (regarding CYP2C9). G296, T301, T304
and S478 amino acids of the enzyme form H-bonds with the ligand.
The docking of both PHLO and RES resulted in one binding position for each ligand (Figure 10,
top). The binding positions of both compounds are shown separately compared to ketoconazole (a
well-known inhibitor of CYP3A4) (Figure 10, PHLO: bottom left, RES: bottom right). These positions
are more than 10 Å distance from the heme iron, overlapping significantly. S119, E122, P197, and R440
amino acid residues of the enzyme stabilize the binding of both ligands through H bonds.
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Figure 9. Left: The binding mode of R-DESMA (space-filling) as docked to the binding pocket of
CYP2C9 enzyme (teal cartoon) above the heme ring (green sticks). Right: The close-up of binding mode
of R-DESMA (green sticks) as docked to the binding pocket of CYP2C9 enzyme above the heme ring
(Fe3+ ion in orange). Interacting enzyme residues are labelled and shown as thin sticks. Interacting
amino acids: G296, A297, E300, T301, T304, and L361; binding energy: −5.93 kcal/mol.
Figure 10. Top: The binding mode of ketoconazole (space-filling, green) superimposed from the
crystallographic image (PDB code 2v0m) and the ligands, PHLO and RES (space filling, yellow, and
pink, respectively) as docked to the binding pocket of CYP3A4 enzyme (teal cartoon) above the heme
ring (teal sticks, iron with orange sphere). Notably, the binding positions of PHLO and RES overlap
significantly; therefore, they cannot be demonstrated separately. Bottom, left: The close-up of binding
mode of PHLO (green sticks) as docked to the binding pocket of CYP3A4 enzyme. Interacting enzyme
residues are labelled and shown as thin sticks. Bottom, right: The close-up of binding mode of RES
(green sticks) as docked to the binding pocket of CYP3A4 enzyme. Interacting enzyme residues are
labeled and shown as thin sticks. Interacting amino acids (both RES and PHLO): N104, R105, R106,
P107, F108, S119, I120, A121, E122, and R440; binding energies: −6.26 kcal/mol (RES) and −6.46 kcal/mol
(PHLO).
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4. Discussion
As it has been reported, flavonoids and their conjugated metabolites interact with serum
albumin [5,43,44] and with several biotransformation enzymes [45–48]. Flavonoids and their conjugated
metabolites reach only nanomolar or low micromolar systemic plasma concentrations [49], in contrast
to some of the colonic flavonoid metabolites [27]. However, there are only limited data regarding the
effects of colonic flavonoid metabolites on proteins involved in pharmacokinetics of drugs. Therefore,
in this study, we investigated the interactions of 24 colonic flavonoid metabolites with HSA and CYP
(2C9, 2C19, and 3A4) enzymes.
3CA, 24DHAP, PYR, and DESMA decreased the fluorescence emission signal of HSA at 340 nm
(Figure 2). Since the inner-filter effects of the metabolites were corrected (Figure S1; Equation (1)), these
observations show that 3CA, 24DHAP, PYR, and DESMA can partly quench the intrinsic fluorescence
of the Trp-214 residue in HSA, in a concentration-dependent fashion. Therefore, it is reasonable to
hypothesize the formation of albumin-ligand complexes [48,50]. Furthermore, HSA strongly increased
the fluorescence emission signal of 2H4MBA at 395 nm (Figure 4). Water molecules can partly quench
the intrinsic fluorescence of aromatic fluorophores [51]. The interaction of these ligand molecules with
albumin results in the partial decomposition of their hydration shell, which consequently leads to the
increase in their fluorescence signal. Based on these principles, 2H4MBA also interacts with HSA. The
binding constants were calculated employing non-linear fitting with the Hyperquad software (Table 1).
Our results suggest that 2H4MBA and DESMA form highly stable complexes with HSA (logK ≈ 5.1),
that are comparable to the binding constant of warfarin-HSA complex (logK = 5.3) [52]. Thus, the
albumin-binding may be an important factor in their pharmacokinetics. Lower stability of PYR-HSA
and 24DHAP-HSA complexes were determined, while 3CA formed poorly stable complexes with HSA
(logK = 4.1).
The interactions of some compounds tested have been examined in previous studies [18,53–56].
The logK value of phenylacetic acid-HSA complex is between 3 and 4 [57,58], and 3M4HPAA (its
hydroxy-methoxy-substituted derivative) has a similar affinity toward bovine serum albumin (logK
= 3.8) [53]. HIPA (logK = 3.8), 4-HBA (no interaction), 24DHBA (logK = 3.2), and 34DHBA (logK
= 3.1) formed no or poorly stable complexes with HSA [18,54–56], which explains why we did not
observe their relevant interactions with albumin in quenching studies. Our results show high affinity
of 2H4MBA toward HSA (logK = 5.1); however, a recent study suggests a considerably lower stability
of 2H4MBA-HSA complex (logK = 3.2) [55]. It may result from the fluorescence emission spectra
of 2H4MBA, overlapping with the emission maximum of HSA (Figure 4), disrupting the precise
determination of the binding constant in a quenching study (performed Zhang et al.) [55]. Previously
reported logK values of 3CA-bovine serum albumin (logK = 4.1) [56] and PYR-HSA (logK = 4.5) [18]
complexes are in a good agreement with our results.
3CA achieves only low nanomolar concentrations in the circulation [27]. We did not find plasma
concentration data regarding 24DHAP; however, it appeared in the circulation after the administration
of Liu Wei Di Huang Wan (traditional Chinese herbal drug) to rats [59]. After the consumption of
mixed berry fruit purée by healthy human volunteers, the concentration of PYR sulfates exceeded
10 µM in plasma samples [60]. Furthermore, after the consumption of black tea extract (2650 mg),
approximately 7 µM peak plasma concentration of PYR was observed in healthy human subjects
(importantly: plasma samples were not treated with sulfatase) [26]. Plasma concentrations of DESMA,
after the dietary intake or high consumption of soy products, show great variability with low nanomolar
values to 0.5 µM [38,61]. After the administration of Decalepis arayalpathra tuber extract to rats, high
concentrations of 2H4MBA (Cmax = 7.7 µM) were quantified in rat plasma [62]. Furthermore, the
orally-administered 4-hydroxy-3-methoxy-benzoic acid (structural isomer of 2H4MBA) was absorbed
and produced micromolar concentrations (Cmax = 5.7 µM) in healthy human volunteers [26]. These
data underscore that the albumin-binding of 24DHAP, PYR, DESMA, and 2H4MBA may have biological
and/or pharmacological importance.
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In ultrafiltration studies, warfarin concentration was increased by PYR and DESMA, while
naproxen concentration was elevated by 2H4MBA in the filtrates (Figure 5). Since HSA is a large
macromolecule (66.5 kDa), HSA and albumin-bound molecules cannot pass through a filter with 30 kDa
molecular weight cut-off value. Therefore, the increase in the concentration of site markers in the filtrate
indicates their displacement from HSA [33]. Considering these principles and our observations, it is
reasonable to hypothesize that PYR and DESMA displaced warfarin from Site I, and 2H4MBA displaced
naproxen from Site II. Nevertheless, the fact that 20 µM concentrations of flavonoid metabolites (vs.
1 µM site marker concentrations) induced no or only slight displacement of warfarin and naproxen
suggests their poor displacing ability vs. both sites. In the same experimental models used, several
flavonoids (with logK values in the range of 5.2-5.7) caused significantly stronger displacement of
warfarin (quercetin, quercetin-3′-sulfate, isorhamnetin, tamarixetin, chrysin, chrysin-7-sulfate, and
7,8-dihydroxyflavone) and/or naproxen (chrysin, chrysin-7-sulfate, and 7,8-dihydroxyflavone) [5,33,48]
compared to the colonic flavonoid metabolites tested in this study. Therefore, it seems to be unlikely
that these microbial metabolites can disrupt the albumin binding of drugs.
In our experiments, DESMA was the sole metabolite tested which strongly inhibited CYP2C9
(Figure 6). In agreement with our observations, 4HBA and 34HPPA did not inhibit [63] while HIPA
inhibited only at very high concentrations (e.g., 100 µM) [64] the CYP2C9 enzyme in previous studies.
As it has been reported, the soy isoflavone daidzein inhibits the CYP2C9-catalyzed hydroxylation
of diclofenac [65]. Furthermore, in the human intestinal tract, a significant amount of daidzein is
biotransformed to DESMA [66]. Therefore, it is reasonable to hypothesize that DESMA may further
increase the inhibitory effect of daidzein on CYP2C9 in vivo. Based on previously reported data, the
peak plasma concentration of DESMA (after the ingestion of 60 g baked soybean powder) can reach
300−500 nM [61].
Under the applied conditions, the statistically significant but weak inhibition of CYP2C19 by
2H4MBA, 34DHBA, HIPA, and DESMA was observed (Figure 7). We did not find any data in the
scientific literature regarding the effects of these compounds on CYP2C19. Qiao et al. reported that
4HBA and 34HPPA did not inhibit the CYP2C19 enzyme [63], in accordance with our study. Based on
these results, it seems to be unlikely that 2H4MBA, 34DHBA, HIPA, and DESMA can cause relevant
interaction with drugs biotransformed by CYP2C19.
Among the 24 metabolites tested, 24DHAP, DESMA, PHLO, and RES significantly inhibited the
CYP3A4 enzyme (Figure 8). Based on our current knowledge, the inhibitory effects of these compounds
on CYP3A4 have not been reported. In previous studies, HIPA did not show relevant inhibition at
1-100 µM range [64] or exerted considerable inhibition only above 50 µM concentrations [67] on the
CYP3A4-catalyzed testosterone hydroxylation. In another studies, 4HBA and 34HPPA [63,68,69] as
well as 4-coumaric acid (the structural isomer of 3CA) [70] did not influence CYP3A4 enzyme. Thus, our
results are consistent with the previously reported data. Despite the fact that RES and PHLO are much
weaker inhibitors of CYP3A4 than ketoconazole, they caused similarly strong inhibition of the enzyme
in the same experimental model as bergamottin did [42] (which shows clinically relevant interaction
with CYP3A4). Therefore, the effects of RES and PHLO on CYP3A4 may cause relevant pharmacokinetic
interactions, while the inhibitory effect of 24DHAP and DESMA does not seem considerable. Based
on previous investigations, PHLO can be absorbed and reach the systemic circulation: after the oral
administration of 160 mg PHLO, approximately 5 µM peak plasma concentrations were determined
in healthy human volunteers [71,72]. However, we did not find any data regarding the plasma
concentrations of RES.
Some colonic flavonoid metabolites (e.g., 33HPPA, 34DHPAA, 4-MC, and DESMA) may
contribute to the positive cardiovascular effects of flavonoids [28,73–75]. Considering the potential
pharmacological importance of microbial flavonoid metabolites, a deeper understanding of their
pharmacokinetic interactions is needed and reasonable. Furthermore, some of the compounds tested
also appear in nature and/or are formed during the biotransformation of other polyphenols as well. For
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example, PHLO derivatives are typically found in plants from the Myrtacae and Rosaceae families [76],
while RES derivatives can be found in rice, wheat, and rye [77].
In conclusion, our results highlight that some microbial metabolites of flavonoids can interact
with proteins involved in the pharmacokinetics of drugs. Because many of these metabolites can reach
relevant concentrations in the circulation (and likely in some tissues), we should consider the potential
interactions of colonic flavonoid metabolites both from the pharmacokinetic and pharmacodynamic
points of view. 3CA, 24DHAP, PYR, DESMA, and 2H4MBA form complexes with HSA. However, only
slight or no displacement of Site I and II markers was observed in the presence of the compounds
tested. Under the applied conditions, DESMA decreased the CYP2C9-catalyzed metabolite formation
while colonic metabolites had only a slight effect on the CYP2C19 enzyme. Furthermore, RES and
PHLO strongly inhibited CYP3A4. Considering the above-listed observations, besides the flavonoid
aglycones and their conjugated derivatives, colonic metabolites may also interfere with the drug
therapy through the development of pharmacokinetic interactions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/3/409/s1,
Figure S1: Absorption spectra of 3-coumaric acid (3CA, 5 µM), pyrogallol (PYR, 5 µM), 2,4-dihydroxyacetophenone
(24DHAP, 5 µM), and O-desmethylangolensin (DESMA, 5 µM) in PBS (pH 7.4).
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